Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

5.75
+0.15002.68%
Post-market: 5.750.00000.00%19:30 EDT
Volume:69.91K
Turnover:397.93K
Market Cap:15.10M
PE:-0.32
High:5.98
Open:5.57
Low:5.30
Close:5.60
52wk High:10.75
52wk Low:1.31
Shares:2.63M
Float Shares:2.13M
Volume Ratio:1.01
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.7100
EPS(LYR):-11.9306
ROE:-2011.64%
ROA:-40.02%
PB:-0.39
PE(LYR):-0.48

Loading ...

Adial Pharmaceuticals files AD04 utility application with USPTO

TIPRANKS
·
Apr 30

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

GlobeNewswire
·
Apr 29

Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program

Reuters
·
Apr 27

Adial Pharmaceuticals completes AD04 demonstration batch production

TIPRANKS
·
Apr 22

Adial completes AD04 demo batch, clearing path for planned Phase 3 trial

Reuters
·
Apr 22

Adial Pharmaceuticals Implements New Executive Equity Compensation Plan

TIPRANKS
·
Apr 10

Adial Pharma grants CEO Cary Claiborne 37,985 restricted stock awards

Reuters
·
Apr 10

Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies

Reuters
·
Mar 24

Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate

Benzinga Earnings
·
Mar 06

Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Dow Jones
·
Mar 06

Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 06

Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%

Reuters
·
Mar 06

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

TIPRANKS
·
Mar 03

Adial Pharmaceuticals Signs Exclusive AD04 Collaboration Framework With Molteni for Europe

Reuters
·
Mar 03

Adial Pharmaceuticals Inc: Engaging With Potential Commercial Partners in United States, to Initiate Its Pivotal Phase 3 Program in Near Term

THOMSON REUTERS
·
Mar 03

Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement

THOMSON REUTERS
·
Mar 03

EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million

Benzinga_recent_news
·
Mar 03